Listed

Arbutus Biopharma Corp: Form 10-Q for the period ended Sep 30, 2016

Filed with the SEC on Nov 3, 2016 and accepted by EDGAR at Nov 3, 2016, 16:49 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-07-01 to 2016-09-30$774.0kus-gaap:Revenues
Revenue9 months2016-01-01 to 2016-09-30$1.7mus-gaap:Revenues
Research and development3 months2016-07-01 to 2016-09-30$15.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2016-01-01 to 2016-09-30$44.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-07-01 to 2016-09-30−$19.0mus-gaap:OperatingIncomeLoss
Operating income9 months2016-01-01 to 2016-09-30−$234.2mus-gaap:OperatingIncomeLoss
Income tax3 months2016-07-01 to 2016-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2016-01-01 to 2016-09-30−$64.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-07-01 to 2016-09-30−$19.6mus-gaap:NetIncomeLoss
Net income9 months2016-01-01 to 2016-09-30−$165.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-07-01 to 2016-09-30−$0.37us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2016-01-01 to 2016-09-30−$3.15us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2016-07-01 to 2016-09-30−$14.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Operating cash flow9 months2016-01-01 to 2016-09-30−$43.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2016-07-01 to 2016-09-30$168.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Capital expenditure9 months2016-01-01 to 2016-09-30$1.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-09-30$26.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-09-30$151.8mus-gaap:AssetsCurrent
Total assetsAt period end2016-09-30$514.7mus-gaap:Assets
Current liabilitiesAt period end2016-09-30$8.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-09-30$98.1mus-gaap:Liabilities
Shareholders' equityAt period end2016-09-30$416.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-16-020766. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.